Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Cancer, treatment using vascular endothelial growth factor

Bevacizumab, a humanized IgG and cetuximab, a chimeric IgGx, are currently marketed in the US for treatment of metastatic colorectal cancer [92, 93]. Bevacizumab neutralizes the biological activity of vascular endothelial growth factor (VEGF), while cetuximab binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Bevacizumab, in combination with IV 5-fluorouracil (5-FU) -based chemotherapy, is indicated for first-line treatment of metastatic colorectal cancer, whereas cetuximab is used in patients refractory to or intolerant to irinotecan-based chemotherapy. The clinical pharmacokinetics of cetuximab are discussed in detail in Chapter 14. [Pg.318]

See other pages where Cancer, treatment using vascular endothelial growth factor is mentioned: [Pg.604]    [Pg.1010]    [Pg.1351]    [Pg.469]    [Pg.506]    [Pg.534]    [Pg.446]    [Pg.366]    [Pg.461]    [Pg.1197]    [Pg.400]    [Pg.514]    [Pg.172]    [Pg.604]    [Pg.1010]    [Pg.444]    [Pg.653]    [Pg.4]    [Pg.458]    [Pg.346]    [Pg.125]    [Pg.464]    [Pg.311]    [Pg.239]    [Pg.252]    [Pg.243]    [Pg.523]    [Pg.244]    [Pg.2208]    [Pg.455]    [Pg.152]    [Pg.816]    [Pg.494]    [Pg.105]    [Pg.169]    [Pg.338]    [Pg.519]   


SEARCH



Cancer factors

Cancer growth

Cancer treatment

Cancer, treatment using

Endothelial

Endothelial growth factors

Endothelialization

Growth factors cancer

Usefulness Factor

Vascular endothelial growth

Vascular growth

© 2024 chempedia.info